This segment focuses on the research and development of novel therapies for liver diseases, particularly non-alcoholic steatohepatitis (NASH). Metacrine's primary focus in this area is MET409, a novel non-bile acid FXR agonist, which has completed a Phase 1b proof-of-concept clinical trial. The company is also developing MET642, currently in a Phase 2a clinical trial for NASH. Research and development activities include preclinical studies, clinical trial design and execution, and regulatory submissions. The company utilizes advanced drug discovery and development methodologies to identify and optimize drug candidates. The patient impact is significant, as NASH is a growing global health concern with limited treatment options. Metacrine aims to improve patient outcomes by providing effective and safe therapies. The company's market positioning is based on its innovative approach to targeting liver diseases. Future opportunities include expanding the pipeline to address other liver diseases and exploring combination therapies. Regulatory and clinical aspects involve navigating the FDA approval process and conducting clinical trials to demonstrate efficacy and safety. Partnerships with other pharmaceutical companies, such as Novo Nordisk, are key to advancing the development of these therapies.

This segment concentrates on the development of therapies for gastrointestinal diseases. The company's research and development efforts include identifying and developing drug candidates for various gastrointestinal disorders. The primary focus is on MET409, which is also being evaluated in combination with empagliflozin in a Phase 2a clinical trial for type 2 diabetes mellitus and NASH. The company employs advanced drug discovery and development methodologies, including preclinical studies, clinical trial design, and regulatory submissions. The therapeutic areas covered include NASH and type 2 diabetes. The patient impact is significant, as these diseases affect a large population. The company aims to improve patient outcomes by providing effective and safe therapies. The market positioning is based on its innovative approach to targeting gastrointestinal diseases. Future opportunities include expanding the pipeline to address other gastrointestinal disorders and exploring combination therapies. Regulatory and clinical aspects involve navigating the FDA approval process and conducting clinical trials to demonstrate efficacy and safety. Partnerships with other pharmaceutical companies are key to advancing the development of these therapies.